CAR T-cell therapy is one of the most advanced treatments in modern cancer care. It has shown remarkable results, including deep and lasting remissions in patients who previously had very limited options.
At the same time, CAR-T is a powerful immune-based treatment, and this means it comes with a distinct set of side effects. The reassuring part is that these effects are well understood, carefully monitored, and in most cases manageable.
Cytokine Release Syndrome (CRS)
The most common side effect of CAR-T therapy is Cytokine Release Syndrome, or CRS. It occurs when the infused CAR-T cells become highly active and release large amounts of inflammatory molecules called cytokines.
In many patients, CRS begins with a fever and may feel similar to a flu-like illness.
In more significant cases, it can affect:
- Blood pressure
- Heart rate
- Breathing
This sounds concerning, but one of the key advances in CAR-T therapy over recent years is how well doctors have learned to manage this reaction. Patients are monitored very closely from the moment the cells are infused. Medical teams track vital signs frequently and perform regular blood tests to detect early signs of inflammation. CRS is graded by severity, and treatment decisions are based on this grading system.
A key medication used is Tocilizumab, which blocks one of the main inflammatory pathways driving CRS. In many cases, patients respond quickly—sometimes within hours. If needed, steroids are added to further calm the immune response, and supportive care such as fluids or oxygen is provided when necessary.
Thanks to these structured protocols, most cases of CRS are controlled effectively and resolve within a few days.
Neurological Side Effects (ICANS)
Another important side effect is neurotoxicity, known as ICANS (Immune Effector Cell–Associated Neurotoxicity Syndrome). This can affect the brain and nervous system.
The earliest signs are often subtle, and may include:
- Difficulty finding words
- Mild confusion
- Trouble writing or concentrating
Because these changes can be mild at first, patients undergo regular neurological checks designed to pick up even small differences. If ICANS develops, doctors usually respond quickly with corticosteroids, which reduce inflammation in the brain. In some cases, preventive anti-seizure medications are also used. Patients are observed closely, and only rarely is intensive care required.
Importantly, in most cases, ICANS is temporary. Patients typically recover fully, with no lasting neurological damage.
Other Side Effects
Beyond CRS and ICANS, CAR-T therapy can also affect the blood and immune system more broadly.
It is common for patients to experience low blood counts in the weeks following treatment. This can increase the risk of infection, cause fatigue, or lead to a higher tendency to bleed. In addition, the immune system may remain weakened for some time after treatment.
Other possible effects include:
- Increased risk of infections in the first months after therapy
- Depletion of normal B-cells, leading to lower antibody levels
- The need for immunoglobulin (IVIG) replacement in some patients
These effects are expected and are managed with preventive medications, monitoring, and supportive care.
Final Perspective
CAR T-cell therapy works by activating the immune system in a very powerful way. The same mechanism that allows it to attack cancer so effectively can also lead to temporary side effects.
What has changed in recent years is not the existence of these side effects, but how well they are understood and controlled. With experienced medical teams, careful monitoring, and established treatment protocols, most side effects are manageable and reversible.
For many patients, especially those with limited alternatives, CAR-T therapy offers not only a new treatment—but a real chance for meaningful recovery.
Another patient completes CAR-T treatment — Latest PET-CT shows no evidence of disease (2026)
Read more patient testimonials >>
Publication date: Match 2026
